A 3-Way Cross-Over, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess Pharmacologic Effects of a 7-Day Exposure to Darifenacin 15 mg o.d. and Tolterodine ER 4 mg o.d. on Cardiovascular Parameters in Healthy Subjects 50 Years of Age and Older.
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2012
At a glance
- Drugs Darifenacin; Tolterodine
- Indications Overactive bladder
- Focus Pharmacodynamics
- Sponsors Novartis
- 23 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2009 Results have been presented at the 39th Annual Meeting of the International Continence Society.
- 17 Jul 2008 New trial record.